Natera, a biopharmaceutical company specializing in cell-free DNA and precision medicine, announced the acquisition of Foresight Diagnostics, a cancer diagnostics company, on December 4th, 2025. According to a company press release, Natera will pay $275 million in upfront fees for Foresight, with an additional $175 million contingent on revenue and reimbursement-based milestones.
The acquisition grants Natera the rights to Foresight’s circulating tumor DNA-based molecular residual disease (MRD) tests, which use the PhasED-Seq technology to track phased variants. Designed to significantly reduce the background error rate compared to traditional single-nucleotide variant-based technologies, Foresight has reported performance with LOD95 of 0.3 parts per million and detection below 0.1 ppm. According to the release, Natera plans to incorporate phased variant detection into its Signatera platform in 2026.
The press release also noted that Natera acquired Foresight because of the company’s “lymphoma leadership,” which Natera’s leadership believes will accelerate the company’s own efforts in that field. Foresight’s CLARITY MRD assay is currently being used in three prospective MRD-driven clinical trials for diffuse large B-cell lymphoma.
“This acquisition reinforces Natera’s position at the forefront of precision oncology,” said Steve Chapman, CEO, Natera, in the release. “Foresight’s phased variant technology and leadership in lymphoma complement Natera’s strong capabilities in personalized MRD testing, improving the value we can deliver to patients, clinicians, biopharma partners and the broader healthcare system.”
“Foresight’s mission has always been to improve the lives of cancer patients worldwide through innovative diagnostics,” said Jake Chabon, CEO, CSO, Co-Founder, Foresight Diagnostics, in the release. “As we join Natera, I’m deeply grateful to our employees, partners and investors who have helped bring us to this moment. Together, we can realize this mission on a far greater scale, accelerating the pace of discovery across both hematologic and solid tumors.”
